Overview
- Axo Longevity raised $5 million in an oversubscribed seed round to expand its preventive health membership across Europe.
- The platform operates in six countries, supported by more than 1,400 laboratory locations and over 19,000 people on its waitlist.
- Its membership combines comprehensive biomarker testing, biological age and health scores, personalized health plans, and repeat testing to track changes over time.
The News
Axo Longevity has secured $5 million in seed funding to expand its preventive health platform, which helps consumers identify potential health risks before symptoms appear. The company currently operates in the UK, Ireland, Spain, Germany, the Netherlands, and Peru through laboratory partners including Randox, Sussex Pathology, Eurofins, MDI Limbach, and Multilab.
Its Axo Longevity Care membership includes two annual blood panels covering 100+ biomarkers, an Axo Health Score, biological age assessment, and personalized health plans. Members receive results based on optimal health ranges and repeat testing after six months to monitor changes and progress.
Industry Perspective
Preventive health is increasingly shifting toward proactive monitoring, with consumers seeking greater visibility into biomarkers and long-term health risks before symptoms emerge. Axo Longevity’s model combines laboratory testing with ongoing tracking and personalized recommendations rather than relying on one-time health assessments.
Strategic Impact
The funding will support expansion of Axo Longevity’s laboratory network, development of its AI health copilot and wearable integrations, and entry into the Nordics, Italy, and Portugal. Its growing European infrastructure and repeat-testing model position the company to build a broader data-driven preventive health ecosystem.
Source: Businesswire
